| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.22 | 4e-05 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.13 | 4e-05 |
| mRNA | JQ-1:vorinostat (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 8e-05 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.21 | 0.0002 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | -0.15 | 0.0004 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.18 | 0.0005 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0006 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0007 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0009 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.16 | 0.001 |